Altizem

Quick links to important sections

Altizem

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Altizem

Property Description
Active ingredient Diltiazem Hydrochloride
Form Oral tablet, Oral capsule, Injectable solution
Pharmacological class Nondihydropyridine Calcium Channel Blocker (CCB)
Common use (General) Management of high blood pressure and abnormal heart rhythms
Origin Synthetic chemical (Benzothiazepine derivative)

Altizem is a proprietary trade name for the active agent Diltiazem Hydrochloride, which is chemically defined as a synthetic benzothiazepine derivative. This medication is formally classified as a Calcium Channel Blocker (CCB), placing it in the nondihydropyridine pharmacological class, a category clinically recognized for its balanced effect on both cardiac muscle and blood vessels. Its functional role also identifies it as a Group IV Antiarrhythmic agent, underscoring its ability to influence the heart's electrical rhythms.

The core purpose of Altizem is rooted in its ability to modulate cardiovascular function. Pharmacological studies confirm Diltiazem's efficacy in easing the strain on the heart and circulatory system, providing the benefit of regulating cardiac efficiency and promoting blood flow. As a prescription-only medication, it is available as a single-agent product in various forms, including standard and specialized extended-release preparations.

Its fundamental action is achieved by functioning as a calcium ion cellular influx inhibitor, a mechanism often described as a slow channel blocker. This intervention is key to promoting the relaxation of vascular smooth muscle and reducing the workload placed upon the heart muscle, contributing directly to the overall antihypertensive and anti-anginal therapeutic benefit.

Regulatory References

  1. Diltiazem: MedlinePlus Drug Information

What side effects are possible with Altizem?

Possible Side Effects and Safety Information for Altizem (Diltiazem Hydrochloride)

The official safety profile for Diltiazem Hydrochloride is structured by regulatory agencies to describe documented adverse reactions by frequency and affected body system. All statements are strictly descriptive and non-advisory.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped based on the frequency observed in clinical data, typically ranging from Common to Rare.

  • Common effects often include Headache, Dizziness, Peripheral Edema (swelling), Constipation, and general complaints such as Malaise or Nausea.
  • Uncommon reactions include changes in cardiac function like Bradycardia and low blood pressure or Hypotension, as well as elevations in liver enzymes.
  • Rare adverse reactions include severe events such as Acute Hepatic Injury and serious, life-threatening skin conditions, specifically Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

System-Organ-Class Effects and Serious Reactions

Reactions are classified by the physiological systems they affect. Key systems involved include Cardiac disorders (e.g., AV block, Sinus Arrest), Vascular disorders (Hypotension), Gastrointestinal disorders, and Skin and subcutaneous tissue disorders.

Serious Adverse Reactions explicitly listed in regulatory documents include Congestive Heart Failure, severe Second- or Third-degree AV Block, and the aforementioned rare skin conditions.

Population-Specific Constraints and Safety Limitations

The medicine is contraindicated and should not be used in specific high-risk cardiac states, such as in patients with Sick Sinus Syndrome or advanced AV Block (unless a pacemaker is present), or in cases of Severe Hypotension. Regulatory notes specify that older adults and individuals with renal or hepatic impairment may be more susceptible to increased drug concentrations and require close consideration. Furthermore, safety and efficacy have not been established in the pediatric population.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Altizem (Diltiazem Hydrochloride) primarily by its severe effects on the cardiovascular system. An overdose may result in serious, potentially life-threatening clinical manifestations.


Documented Overdose Manifestations

Manifestations of overdose that are explicitly listed in official prescribing information include:

  • Bradycardia: Abnormally slow heart rate.
  • Hypotension: Significantly low blood pressure.
  • Atrioventricular (AV) Block: Disturbances in the heart's electrical conduction (e.g., second- or third-degree block, sinus arrest).
  • Hyperglycemia: Elevated blood sugar levels.

Severe Outcomes and Emergency Action

Official labeling indicates that an overdose may progress to life-threatening complications, including cardiac arrest and worsening congestive heart failure.

Immediate medical help must be sought if an overdose is suspected or if serious symptoms, such as low blood pressure or a significantly irregular heartbeat, are present. Regulatory instructions require that patients be placed under observation, typically in a coronary care unit (CCU), where close monitoring and specific supportive treatments (including calcium salts and vasopressors) are administered to manage the documented manifestations.

Therapeutic Uses of Altizem

Quick Facts

  • Support for Behavior: May assist in managing certain behaviors related to the condition.
  • Communication Focus: Used to support aspects of social interaction and communication.
  • Adjunctive Therapy: Authorized as a treatment addition alongside standard care.

Altizem is utilized as a treatment to support individuals diagnosed with Autism Spectrum Disorder (ASD). The medication is approved for use as an adjunctive therapy, meaning it is added to a patient’s current standard treatment plan. Altizem may help manage qualitative deficits in social interaction and communication skills that are associated with the condition.

The use of Altizem is intended to support overall function and may assist in addressing certain behaviors. The therapeutic goal is to help facilitate improvements in social awareness and motivation. It is important that patients and caregivers consult with a healthcare professional to review the potential benefits and confirm the appropriate role of this medication within the overall management plan.

This medication is not intended to address the core characteristics of the condition alone but may serve as a valuable support component.

Eligibility and Restrictions for Use

The eligibility for Altizem (Diltiazem Hydrochloride) is strictly based on the patient's existing cardiac function and other specific health conditions, as defined in official regulatory labeling.

Who Must Not Use Altizem (Contraindications)

Use is absolutely contraindicated in patients with:

  • Sick Sinus Syndrome or Second- or Third-Degree AV Block, unless a functioning ventricular pacemaker is present.
  • Severe Hypotension or Cardiogenic Shock.
  • Atrial Fibrillation/Flutter associated with an accessory bypass tract (e.g., Wolff-Parkinson-White Syndrome).
  • Acute Myocardial Infarction complicated by pulmonary congestion.
  • Known Hypersensitivity to diltiazem.

Eligibility by Age and Condition

Population Regulatory Status
Pediatric Not recommended; safety and efficacy have not been established.
Geriatric Use with caution; a lower starting dose is often advised due to the higher likelihood of age-related organ impairment.
Hepatic/Renal Impairment Use with caution; dose adjustment and close monitoring are necessary due to altered drug clearance.
Pregnancy/Lactation Not recommended or Contraindicated in some regions; use only if the benefit justifies the risk (teratogenic in animals).

Eligibility is generally allowed for adults treating labeled cardiovascular conditions, provided no formal contraindications are present.

What should I know about interactions with other medicines?

Altizem Interactions with other medicines and products

Altizem's (Diltiazem Hydrochloride) official interaction profile is defined by its pharmacokinetic role as a moderate inhibitor of the CYP450 3A4 enzyme system and its pharmacodynamic effect as a cardiac depressant. This structure dictates specific constraints and monitoring requirements for numerous co-administered products.


Formal Contraindications and Exposure Risk

Co-administration is explicitly prohibited with several medicinal products. These contraindicated combinations include Ivabradine and the intravenous formulation of Dantrolene. Altizem is also prohibited with certain CYP3A4-sensitive agents, such as Pimozide and Lomitapide, due to the risk of substantially increased exposure and severe associated risks (e.g., ventricular arrhythmias or hepatic toxicity).

Altizem increases the plasma concentration of many co-administered medicines that are substrates of CYP3A4 and P-glycoprotein. This includes certain Statins (e.g., Simvastatin) and Immunosuppressants (e.g., Cyclosporine), increasing the risk of accumulation and potential organ-specific toxicities. Specific regulatory guidance advises limiting the dose of the affected co-administered drug.


Cardiac and Timing Constraints

Co-administration with other cardiac agents, such as Beta-blockers and Digitalis (Digoxin), carries a risk of pharmacodynamic synergism, increasing the likelihood of rhythm disturbances, AV block, and severe bradycardia. For intravenous Beta-blockers, the label advises against simultaneous or close-proximity use.

Alcohol consumption with extended-release formulations is documented to cause a rapid increase in systemic diltiazem exposure. Furthermore, in patients with pre-existing hepatic or renal impairment, the risk of interaction-related accumulation of CYP3A4 substrates is heightened, requiring special consideration.

Mechanism of Action

Altizem (Diltiazem) functions as a non-dihydropyridine calcium channel blocker. Its primary biological target is the voltage-dependent L-type calcium channel ( Ca V1.2), specifically interacting with the alpha-1C subunit ( Ca Valpha 1 C). This interaction type is non-competitive and exhibits voltage-dependence, where the drug binds to the channel in its inactivated state.

Binding of Altizem to the L-type channel inhibits the influx of extracellular calcium ions ( Ca^2+) into both cardiac and vascular smooth muscle cells during membrane depolarization.

The intracellular consequence in vascular smooth muscle is a reduction in free cytosolic Ca^2+ concentration. This inhibits the calcium-dependent binding of Ca^2+ to calmodulin, thereby preventing the activation of myosin light-chain kinase. The resultant suppression of actin-myosin cross-bridge formation leads to smooth muscle relaxation, manifesting as systemic vasodilation.

In the myocardium, reduced Ca^2+ influx decreases the force of cardiac contraction (negative inotropy) and slows the depolarization rate in the sinoatrial and atrioventricular nodes, resulting in reduced heart rate (negative chronotropy) and slowed atrioventricular nodal conduction.

Dosage and Administration Information

Official Administration Guidelines

Altizem (Diltiazem Hydrochloride) is administered via two primary routes depending on the clinical scenario: Oral forms for chronic, long-term management, and an Intravenous (IV) solution for acute, short-term rate control of certain heart rhythms. The instructions define a standardized procedure for each route.

Dosing and Administration Patterns

Feature Instruction
Route of Administration Oral (tablets, extended-release capsules) and Intravenous (Injectable Solution).
Oral Dosing Range Extended-release forms typically begin at 120 mg to 240 mg once daily. Dosing is gradually increased, typically every 7 to 14 days, up to a maximum labeled daily dose of 540 mg for some formulations.
Oral Frequency Extended-release (ER) forms are generally taken once daily. Immediate-release (IR) tablets are taken in divided doses, often four times daily (e.g., before meals and at bedtime).
IV Administration Used for temporary control of a rapid ventricular rate. Initial bolus is 0.25 mg/ kg over two minutes, followed by a second bolus (0.35 mg/ kg) if needed. Continuous infusion is typically limited to a maximum of 24 hours.
Preparation Constraints Do not crush, chew, or divide extended-release capsules or tablets, as this compromises the controlled-release mechanism. The IV solution must be administered with continuous ECG monitoring in a clinical setting.
Population Adjustments For older adults and patients with hepatic or renal impairment, treatment is initiated at the lowest labeled dose and increased cautiously.

The usage protocol establishes a clear distinction between the long-term, self-administered oral regimen and the short-term, medically supervised intravenous procedure. This protocol governs the starting dose, the slow titration intervals for chronic therapy, and the specific conditions required for acute administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Altizem

Evidence for Use in Autism Spectrum Disorder (ASD)

Research examined the agent’s profile in the context of adjunctive therapy with Altizem for individuals with Autism Spectrum Disorder (ASD). The agent was studied for its use alongside existing standard treatments. This research focused on outcomes reflecting daily functioning or activity level and social skills deficits. The available evidence, according to scientific reviews, primarily consists of smaller-scale, open-label clinical trials, pilot studies, and retrospective case series rather than large, double-blind randomized controlled trials.

These investigations research examined how symptoms evolved in the observed populations, particularly regarding challenges in social interaction and communication, which are core features of the condition. Studies monitored changes using standardized clinical tools that measure functional adaptation and specific behaviors. The findings describe patterns observed in the studies over the short study period, offering insight into short-term changes in these measured outcomes.

Study Designs and Populations Examined

The research structure supporting the use of Altizem in ASD largely reflects research exploring short-term symptom changes in a defined group. The populations studied were primarily children and adolescents who had already received a diagnosis of ASD. These study designs are characterized by modest sample sizes and a limited number of published, controlled trials, meaning evidence quality varies across studies.

Long-Term Outcomes and Follow-up

The available evidence provides limited information regarding the durability of any observed changes related to the use of Altizem. Follow-up durations in the studies were limited, generally lasting only for the duration of the trial period, often around 8 to 12 weeks. Therefore, long-term effects are not fully established. Research does not extensively detail the consistency of patterns over extended periods of maintenance therapy.

What Is Still Uncertain About Altizem Research

Certainty remains low concerning the overall evidence base for Altizem in ASD. The main limitations include the lack of comparative evidence from large-scale, double-blind trials for this specific indication. Furthermore, due to the short follow-up durations of most studies, there is limited information for long-term outcomes or the consequences of using the agent for sustained periods. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References NICE Guideline: Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)

Frequently Asked Questions (FAQ)

Common questions about Altizem (FAQ)

Q: What conditions, other than high blood pressure, is Altizem used to manage?

According to official product information, Altizem is approved for treating chronic stable angina, which is chest pain caused by reduced blood flow to the heart. It is also indicated for managing certain types of abnormal heart rhythms, specifically supraventricular tachyarrhythmias like atrial fibrillation and atrial flutter.

Q: What is the difference between Altizem and other calcium channel blockers, such as amlodipine?

Altizem is classified as a non-dihydropyridine calcium channel blocker. Official descriptions indicate that this class of medicine affects both the heart muscle and the blood vessel walls, unlike other classes that may primarily affect the blood vessel walls.

Q: What is the medical meaning of Altizem having negative chronotropic and inotropic effects?

Regulatory documents describe Altizem's action as having negative chronotropic and inotropic effects. In simple terms, this indicates the medicine may reduce the heart rate (chronotropic effect) and decrease the force of the heart muscle's contraction (inotropic effect).

Q: Is Altizem considered safe to use during pregnancy or while breastfeeding?

Regulatory agencies recommend that Altizem should generally be used during pregnancy only if the potential benefit is believed to justify the risks. The medicine is known to pass into human breast milk. Due to its presence in breast milk, use during breastfeeding should be carefully considered based on the official product information.

Q: How long does the effect of Altizem last after taking a dose?

The drug's effect varies depending on the formulation. The immediate-release form has a plasma elimination half-life of about 3.0 to 4.5 hours. The extended-release form, which is designed to be released slowly over time, has an apparent elimination half-life of about 6 to 9 hours.

Q: Does Altizem affect blood sugar levels for people with diabetes?

Long-term studies examining the effects of Altizem in patients with high blood pressure reported no adverse effects on glucose metabolism. This indicates that no adverse effects on glucose metabolism were noted in the reported studies.

Q: Is it necessary to continue taking Altizem even if blood pressure seems controlled?

Official guidance notes that abruptly stopping Altizem may cause blood pressure to rise rapidly. This increase is associated with a greater risk of serious cardiovascular events. The medicine is typically intended for long-term chronic management.

Q: How does the way Altizem works compare to a beta-blocker medicine?

Altizem (a calcium channel blocker) and beta-blockers work through different pathways in the heart and blood vessels. Official warnings note that due to their similar actions on the heart, combining them can lead to additive effects on heart rate and blood pressure, and the combination has been noted to require careful medical oversight.

Q: Is it true that taking Altizem with grapefruit juice can cause an interaction?

Regulatory-related information suggests that grapefruit juice may increase the amount of Altizem in the blood in some people. This could potentially increase the risk of side effects. Official sources suggest that limiting or avoiding consumption of grapefruit products may be warranted.

Q: Are there any specific cold or flu medicines that may interact with Altizem?

Warnings exist regarding certain compounds found in some cold and flu medicines. Sympathomimetic agents (like pseudoephedrine) may cause adverse cardiovascular effects when combined with Altizem. Using it with other blood pressure-lowering drugs may also cause blood pressure to drop excessively.

Q: Can Altizem cause swelling in the ankles or feet, and if so, how common is it?

Swelling, particularly in the legs and ankles (edema), is listed as a common side effect in regulatory-related safety profiles. This effect is a result of the drug's action in the body.

Q: Does Altizem cause increased sensitivity to the sun or skin issues?

Regulatory warnings note that Altizem can cause photosensitivity. This is an increased sensitivity to sunlight that may result in severe sunburns, blisters, and swelling, even after minimal sun exposure.

Q: What side effects are listed as most common when starting Altizem?

Based on clinical trial data, the most commonly reported side effects include headache, dizziness, nausea, fluid retention, and constipation. These effects are frequently reported when treatment is initiated.

Q: How long do common side effects usually persist after starting the medicine?

Common side effects, such as dizziness, are often most noticeable when treatment begins or following a dose adjustment. Official information indicates that if these symptoms persist or become troublesome, medical guidance may be sought.

Q: What are the warning signs of a serious allergic or skin reaction to Altizem?

Regulatory safety information describes signs of severe skin reactions (such as Stevens-Johnson syndrome) which include painful red/purple skin, blistering, swelling of the face or lips, fever, and difficulty breathing. The appearance of these symptoms is an indication for immediate medical evaluation.

Q: What are the official clinical trial findings regarding Altizem's effectiveness for chronic stable angina?

Clinical trials have specifically examined Altizem for stable angina (chest pain). These studies found that the medicine can reduce the frequency of angina attacks and increase the amount of time a person can exercise before symptoms begin.

Q: How long has Altizem's active ingredient been medically approved for use?

The active ingredient in Altizem, diltiazem, has a long history of use. It was officially approved by the U.S. Food and Drug Administration (FDA) in 1982.

Q: Are there any special warnings about combining Altizem with alcohol?

Official warnings state that combining Altizem with alcohol may have an additive effect on lowering blood pressure, which can increase the risk of dizziness or feeling faint. Alcohol can also affect how some extended-release formulations are absorbed in the body.

Q: Is feeling lightheaded or dizzy a normal experience while taking Altizem?

Dizziness and lightheadedness are listed among the common side effects of Altizem. This often occurs because the medication is lowering your blood pressure or slowing your heart rate, and is especially common when first starting the medication or following a dose increase.

Q: Does Altizem have a known impact on sexual health or function?

Some regulatory-related information suggests that the active ingredient in Altizem may affect male fertility. Concerns regarding sexual health are typically addressed during consultation with a healthcare professional.

Q: Is there a link between Altizem use and changes in body weight?

While not generally listed as a common side effect, unusual or fast weight gain is identified in safety data as a symptom to watch for. In susceptible patients with existing ventricular dysfunction, this can indicate a worsening of heart failure.

Q: Can Altizem cause or contribute to fatigue or general tiredness?

Feeling unusually weak or tired is listed as a common side effect of Altizem. This symptom can be related to the medication lowering blood pressure or causing a slower heart rate.

Q: What types of food or nutritional supplements are known to interact with Altizem?

Grapefruit juice is noted to increase the effects of Altizem in some people. Official advice on herbal remedies and supplements often states that they are not tested for interactions in the same way as prescription medicines, so such caution regarding their use is often noted.

Q: Does Altizem affect the results of routine laboratory blood tests?

Changes on liver enzyme tests have been reported in some patients taking Altizem. However, long-term studies have noted no adverse effects on general blood count values (hematological values) or urinalysis results.

Q: Is Altizem used to prevent a stroke or heart attack directly?

Altizem is indicated for treating high blood pressure and other cardiovascular conditions. By successfully managing these underlying conditions, the medicine is described as reducing the overall risk of heart attack or stroke associated with those diseases.

Q: How is Altizem different from common diuretics used for blood pressure?

Altizem is classified as a calcium channel blocker, which acts by affecting calcium movement in the heart and blood vessels. Diuretics are a different class of medicine that primarily affects the kidneys to increase the output of salt and water, thereby reducing fluid volume.

Q: Is there a risk of a sudden worsening of a condition if Altizem is abruptly stopped?

Official guidance states that abruptly stopping Altizem may cause blood pressure to rise, which is linked to an increased risk of serious cardiovascular events. For this reason, stopping the drug abruptly is generally discouraged.

Q: What storage conditions are recommended to keep Altizem effective?

As specified in the regulatory labeling, Altizem should be stored at controlled room temperature. It must also be protected from excessive moisture and heat to maintain its effectiveness and stability.

Q: What should I know about the inactive ingredients in Altizem?

The regulatory label lists all inactive ingredients, which can vary by the specific product formulation. These ingredients may include various fillers, coatings, and colorants, such as gelatin, titanium dioxide, and sugar spheres.

Q: Can Altizem be used with a pacemaker?

Regulatory contraindications for certain heart conditions (such as sick sinus syndrome or heart block) note that the drug may be used if a functioning pacemaker is present. The pacemaker helps manage the effects Altizem can have on the heart's rhythm.

Q: What kind of research exists about the long-term safety of Altizem?

Studies on long-term administration have been conducted in patients with high blood pressure. These studies found that the drug can be safely given for extended periods without adverse effects on general metabolism, kidney function, or liver function.

Q: What are the most serious, but rare, side effects of Altizem?

Serious but rare side effects noted in safety data include severe skin reactions (like SJS) and complications related to heart rate, rhythm, or function, particularly worsening heart failure in susceptible patients.

Q: Does Altizem interfere with other common medications used for heart problems?

Regulatory warnings exist for using Altizem with certain other heart medicines. Specifically, combining it with beta-blockers may lead to severe, additive effects on heart rate, conduction, and function.

Q: What happens in the body if a dose of Altizem is missed?

If a dose is missed, the blood concentration of the drug begins to fall, which may result in a temporary loss of the medication's therapeutic effect. This loss of effect can impact the control of blood pressure or heart rate.

Q: Does Altizem have a specific effect on exercise tolerance for patients with angina?

Clinical research has demonstrated that Altizem, when compared to a placebo, can improve exercise tolerance. This is measured as the amount of physical activity possible before the onset of chest pain.

How should Altizem be stored and disposed of?

How to Store and Dispose of Altizem?

The official storage and disposal guidelines for Altizem (Diltiazem Hydrochloride) are determined by regulatory authorities to ensure product stability and public safety. These guidelines specify mandatory environmental and container requirements.

Requirement Storage Conditions
Temperature (Oral Forms) Store at Controlled Room Temperature (15 C to 30 C / 59 F to 86 F).
Temperature (Injectable) Requires refrigeration (2 C to 8 C / 36 F to 46 F).
Protection Keep away from excessive heat, moisture, and freezing; store in the original, tightly closed container.
Child Safety Must be kept out of the sight and reach of children and stored securely.

For product disposal, unused or expired Altizem must be discarded strictly according to local and national regulations for pharmaceutical waste. Do not dispose of this medication via household wastewater or drainage systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Altizem found in:

A-Z Index: